Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab.
Sfikakis
Petros P
PP
First Department of Propedeutic Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece. psfikakis@med.uoa.gr
Markomichelakis
Nikos
N
Theodossiadis
George P
GP
Grigoropoulos
Vlassis
V
Katsilambros
Nikos
N
Theodossiadis
Panayiotis G
PG
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab